Eleva Secures up to EUR 60 million to Advance a Drug Candidate, Appoints New Board Member

Eleva, a manufacturer of superior biologics, has secured up to EUR 60 million in funding from Zukunftsfonds Heilbronn (ZFHN). The funds will help advance one of its drug candidates, CPV-101, to stages that will facilitate further investment from venture capitalists and/or pharmaceutical companies. Eleva also announced the addition of Dr. Ralf Smit to its Executive […]

InfoQuest Limited

6 ม.ค. 64
1 292 293 294 295 296 389